SURGICAL INNOVATIONS GROUP PLC

Business and Financial Review • Jan 14, 2019

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 9299M

Surgical Innovations Group PLC

14 January 2019

Surgical Innovations Group plc

("Surgical Innovations" or the "Group")

Year-end Trading Update

Surgical Innovations Group plc (AIM: SUN), the designer and manufacturer of innovative technology for minimally invasive surgery, provides an update on trading for the year ended 31 December 2018.

Trading was significantly stronger in the second half of the year, resulting in Group revenue for the full year of approximately £11.0m. This represents growth of approximately 25% over 2017, with underlying revenue growth (adjusted for the effect of the acquisition of Elemental Healthcare Limited in August 2017) of approximately 8%.  Gross margin was within target range and the resulting increase in profit before tax is anticipated to be in line with Board expectations and market consensus.

The Group continued to be cash generative, with closing net cash balances of approximately £0.36m, compared with net debt at the start of the year of £0.73m.

Audited results for the year ended 31 December 2018 will be released in mid-March 2019.

For further information contact:

Surgical Innovations Group Plc	www.sigroupplc.com
Nigel Rogers, Executive Chairman	Tel: +44 (0)113 230 7597
Melanie Ross, COO and CFO
Walbrook PR (Financial PR & Investor Relations)	Tel: +44 (0)20 7933 8780 or si@walbrookpr.com
Paul McManus	Mob: +44 (0)7980 541 893
Lianne Cawthorne	Mob: +44 (0)7584 391 303
N+1 Singer (Nominated Adviser and Broker)	+44 (0)20 7496 3000
Richard Lindley
Rachel Hayes

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

TSTSFUFMFFUSELF